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Real WoRld MaNageMeNt aNd Costs iN UNReseCtable MetastatiC 
MelaNoMa (MM) PatieNts: UPdate of a Pilot stUdy based oN aN 
iNstitUtioNal PatieNt RegistRy
Strens D.1, Specenier P.2, Peeters M.2
1Realidad, GRIMBERGEN, Belgium, 2University Hospital Antwerp, Edegem, Belgium
Objectives: To assess the management and associated lifetime costs in MM patients 
as from the diagnosis of unresectable metastatic disease until death. MethOds: A 
retrospective patient chart review was performed at the Antwerp University Hospital 
to obtain data on medical consumption related to the management of unresectable 
MM (uMM). A complete registry of all melanoma patients who visited the hospi-
tal between 2007 and May 2013 was compiled. Eligible for this retrospective chart 
review were patients with uMM with sufficient data available and who deceased 
before May 2013. Data on demographics, disease characteristics and management 
of uMM were collected. Direct costs were calculated by multiplying each item of 
resource use with its unit cost (2013, € ) using the Belgian public health care payer’s 
perspective (PHCP) and patient’s perspective. Average (bootstrap 95%CI) overall costs 
per patient were calculated. Results: Out of 338 registered melanoma patients, 
35 were eligible and included in this chart review. The median overall survival time 
(OS) in all patients was 6.2 months. 88.6% (n= 31) of patients were treated by sys-
temic treatment(s) of which 17% (n= 6) received up to 4 different treatment lines. 
Ten patients received “new drugs”: ipilimumab (1 to 4 cycles): 10; vemurafenib: 2. 
Fifty-six (41%) of the 137 hospitalizations were for treatment administration. The 
mean overall cost per patient was € 43,429 (bootstrap 95% CI: 33,372 - 54,351), of 
which € 42,367 (95%CI: 32,481 - 52,976) was reimbursed. The PHCP cost was driven 
by systemic treatments costs (46% of cost). Mean PHCP cost was € 87,468 (95 % CI: 
77,372-97,307) for patients treated with “new drugs” versus € 24,327 (95 % CI: 18,617 - 
30,634) for patients not treated with “new drugs”. Median OS was 9 and 4.9 months, 
respectively. cOnclusiOns: Management of uMM results in considerable costs for 
the PHCP, mainly driven by systemic treatment costs.
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Objectives: Few recent data are available on breast cancer treatment costs, espe-
cially by stage of the disease at diagnosis. This study was designed to estimate the 
management costs in breast cancer for the first 5-year period following diagno-
sis. Costs have been distinguished by stage of severity. MethOds: A patient-level 
analysis was performed from a French physician survey database, collecting data 
on patient demographics, cancer history from diagnosis and treatment patterns. 
Data were extracted for all breast cancer cases with at least 1 year of follow-up after 
diagnosis using data collected from 2011 to 2012. Cost analyses were conducted 
from a health care payers’ perspective adjusting for stage (stages I-IV) at diagnosis 
and year from diagnosis. Results: A total of 1,157 patients were included in the 
analysis. The stages at diagnosis distribution was respectively from stage I to IV 
29.7%, 39.2%, 15.0% and 16.1%. The mean (SD) age at inclusion was 62.5 (12.4) and 
the mean (SD) time from diagnosis was 5.0 years (5.1). The mean annual cost (SD) 
over the 5-year period after diagnosis was ranging from 4,293€ (9,526€ ) for stage I 
to 12,111€ (19,070€ ) for stage IV. The mean (SD) annual costs for the 1st year after 
diagnosis were estimated at 11,647€ (9,883€ ), 13,226€ (11,575€ ), 17,254€ (14,535€ ) 
and 24,003€ (24,888€ ), respectively for stage I to IV at diagnosis. The main cost con-
tributors in early stages were radiotherapy and surgery while cytotoxic treatments, 
hormonotherapy and supportive care droved it for the late stage. The mean annual 
costs for the following years after diagnosis (2nd to 5thyear) decreased, ranging from 
1,827€ (8,964€ ) for Stage I to 5,370€ (10,662€ ) for stage IV. cOnclusiOns: : The mean 
annual cost was strongly related to the clinical stage at diagnosis and the year from 
diagnosis. These estimates could be useful to populate models that explore impact 
of treating and preventing breast cancer.
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Objectives: To systematically review the humanistic and economic burden of 
cancer-related venous thromboembolism (VTE). MethOds: A literature search 
was carried out on Pubmed, Cochrane Central Register of Controlled Trials, Econlit, 
Science Direct, JSTOR, Oxford Journals and Cambridge Journals. The search was 
limited to humanistic studies published from January 2000 to December 2012. 
Additional studies were also identified by searching reference lists of relevant 
published reviews and included studies. The identified studies were indepen-
dently reviewed by two reviewers against pre-determined inclusion and exclu-
sion criteria. A quality assessment of the selected studies was also conducted by 
using standard methods . The data of selected studies were extracted onto a data 
extraction form and consequently synthesized. Results: Fifty five studies were 
included in our review. It was found that cancer patients experience between 
2-fold and 20-fold higher risk of developing VTE in comparison to non-cancer 
patients. Cancer patients are more likely to experience a VTE event in the first 3 
or 6 months after cancer diagnosis and the onset of chemotherapy. Additionally, 
an increased risk of VTE in patients with distant metastases and certain types of 
cancer (i.e. pancreatic or lung) was identified. VTE strongly affects the prognosis 
of cancer patients as it has been found that it is a leading cause of death in this 
group of patients. The annual average total cost for cancer patients with VTE was 
found to be almost 50% higher compared to that of cancer patients without VTE 
nities through the utilization of allied health professionals. MethOds: Two local 
CPHHD programs with prospective randomized controlled trial designs (a virtual 
team care intervention aimed at reducing depressive symptoms in older adults 
with depression and cardio-metabolic syndrome, and a patient navigator program 
to increase mammography screening for breast cancer) provided the underlying 
data for this analysis. The programs collected detailed resource use data along 
with several clinical measures. Costs were measured from a payer perspective. 
The navigator program involved in-person or remote navigator consultations, and 
costs were based on a wage rate of $15 per hour. The depression program involved 
multiple services and all costs reflected institution-specific billing data. Results: 
There were 949 patients in the patient navigator intervention. On average, these 
patients received 8.28 minutes of navigator services per patient over the phone and 
1.23 minutes via in-person visits, translating to a per-patient cost of $2.38. For the 
six patients enrolled in the team care intervention for depression, resources used 
included social worker case management and individual psychotherapy, translating 
to program costs of $145 per patient over 12 months. Spillover health care service 
costs were similar between the intervention and control groups (intervention = 
$55 per patient, control = $64 per patient). cOnclusiOns: Costs are an important 
consideration for evaluating pilot, team-care based interventions to improve patient 
health. The two programs evaluated here offer insight into the potential impact of 
interventions that employ allied health professionals and demonstrate a relatively 
low cost per patient. Future work will examine these costs in comparison with 
measured effects of the program.
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Objectives: To investigate the self-reported burden imposed by care of lung 
cancer (LC) patients in the European Union (EU). MethOds: The study included 
respondents to the 2010 and 2011 EU National Health and Wellness Survey from 
France, Germany, Italy, Spain, and the UK who reported being caregivers for a rela-
tive with LC versus respondents who did not report being caregivers for a relative 
with any condition (control). Outcome measures included Short Form (SF)-6D 
health state utilities and mental and physical health status (all derived from the 
SF-12v2), stress-related comorbidities, health care resource use during the past 
6 months, and work/activity impairment during the past week using the Work 
Productivity and Activity Impairment (WPAI) questionnaire. Productivity losses 
were converted into costs using the human capital method by applying median 
hourly wages per country (from Eurostat 2006 personal income inflated to 2010) 
to the total number of hours lost using results from WPAI. Multivariable analyses 
were used to test the potential impact of LC patient caregiving on health care 
resource use and work/activity impairment, as well as costs specifically associated 
with work impairment. Results: A total of 107 caregivers for patients with LC and 
103,868 non-caregivers were identified. Compared with non-caregivers and adjust-
ing for covariates, caregivers had higher mean levels of impaired presenteeism 
(27.1% vs. 14.8%), overall work impairment (32.4% vs. 18.0%), and activity impair-
ment (32.8% vs. 21.8%; all p< 0.005); higher odds of impact across all measures 
of the WPAI including absenteeism (all p< 0.01); and higher annual costs associ-
ated with impaired presenteeism (€ 5,672 vs. € 3,429) and overall work impairment 
(€ 6,905 vs. € 4,147; both p< 0.05). Health care resource utilization and mean level 
of absenteeism did not differ significantly. cOnclusiOns: LC patient caregiving 
in the EU is associated with significantly higher work/activity impairment and 
related costs relative to non-caregivers. Costs associated with LC caregiver burden 
deserve further attention.
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Objectives: To determine direct medical costs of treating patients with Chronic 
Lymphoid Leukemia (CLL) from the Brazilian Public Healthcare System perspec-
tive. MethOds: A retrospective longitudinal analysis of the Government admin-
istrative claims database (Datasus) was performed. Eligibility criteria were patients 
starting CLL (ICD-10 code C911) chemotherapy from Jan/2008 to Dec/2011, with 
complete information and no inconsistency in date of birth, gender. Outpatient 
and inpatient databases were combined through deterministic linkage. Outcome 
was direct medical costs (DMC), calculated as the sum of the medical claims for 
each patient included in the analysis, for a maximum period of 5 years or death or 
loss of follow-up, whichever comes first. DMC was categorized in chemotherapy, 
hospitalizations, and other outpatient costs. Results: From 5100 patients with CLL 
identified in the database, 613 met eligibility criteria. Median follow-up time was 25 
months. This population cohort had 54% males with average age at start of treat-
ment of 66.4 ± 11.7 years. Patients received an average of 12.0 ± 9.4 months of chemo-
therapy treatment, with 71% of them treated by one type of chemotherapy regimen. 
Total DMC in this population was R$ 7,021,631.48 (average cost of R$ 6,404.52 ± 
6,133.37 per patient-year), from which R$ 5,384,552.12 (77%) are related to chemo-
therapy, R$ 1,062,978.98 (15%) to hospitalizations and R$ 574,100.38 (8%) to other 
outpatient costs. Outpatient laboratory exams accounted for 6% (R$ 397,050.07) of 
total DMC. 30 (5%) patients underwent radiotherapy treatment, with total costs of 
R$ 53,944.96 (< 1% of DMC). A total of 862 hospitalizations were identified in 287 
(46.8%) patients, with an average cost of R$ 1,233.15 ± 3,879.86 per hospitaliza-
tion. cOnclusiOns: Patients with CLL represent a significant economic burden 
to the public health system. Chemotherapy and hospitalization costs accounts for 
more than 90% of the total costs.
